<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284320</url>
  </required_header>
  <id_info>
    <org_study_id>GISG-14</org_study_id>
    <nct_id>NCT03284320</nct_id>
  </id_info>
  <brief_title>Retrospective Study in Sarcoma Patients</brief_title>
  <acronym>ReTraSarc</acronym>
  <official_title>Retrospective Study to Evaluate Efficacy and Safety of Trabectedin (Yondelis®) in Sarcoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this trial is to evaluate efficacy and safety of treatment with Trabectedin
      in a large cohort of German patients with soft tissue and bone sarcomas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>- Progression free survival (PFS)</measure>
    <time_frame>At the time of every treatment documentation up to the end of treatment, approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- Overall survival (OS)</measure>
    <time_frame>At the time of every treatment documentation up to the end of treatment, approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CTCAE (Common Terminology Criteria for Adverse Events) 4.03</measure>
    <time_frame>At the time of every treatment documentation up to the end of treatment, approximately 2 years</time_frame>
    <description>Safety Evaluation according to toxitiy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Sarcoma of Bone</condition>
  <condition>Sarcoma of Soft Tissue</condition>
  <condition>Drug Therapy</condition>
  <condition>Treatment Outcome</condition>
  <condition>Adult</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with soft tissue and bone sarcomas treated with Trabectedin
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed soft tissue or bone sarcomas treated with at
             least one cycle of Trabectedin in any line of therapy.

          -  Age ≥18years at start of therapy with Trabectedin

          -  Informed Consent

          -  Patients already deceased may be included when the treating physician is able to
             determine the presumptive consent

        Exclusion Criteria:

          -  No follow-up data available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Pink, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Greifswald</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Reichardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarcoma Center Berlin-Brandenburg; HELIOS Hospital Berlin Buch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Pink, MD</last_name>
    <phone>+49 33631 7 3527</phone>
    <email>daniel.pink@helios-kliniken.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Reichardt, MD</last_name>
    <phone>+49 30 9401 54800</phone>
    <email>peter.reichardt@helios-kliniken.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medicine Greifswald, Department of Internal Medicine C</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Pink D, Bertz-Lepel J, Busemann C, Bitz U, Reichardt P. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma. Onkologie. 2012;35(5):249-52. doi: 10.1159/000338342. Epub 2012 Apr 23.</citation>
    <PMID>22868503</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

